Bioorganic & Medicinal Chemistry Letters 28 (2018) 1111–1115 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine b-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation a,⇑ b a c,e a Jonathan D. Low , Michael D. Bartberger , Yuan Cheng , Doug Whittington , Quifen Xue , d a a,⇑ Stephen Wood , Jennifer R. Allen , Ana E. Minatti Department of Medicinal Chemistry, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA Department of Molecular Engineering, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA Department of Molecular Engineering, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA article i nfo abstract Article history: The diastereoselective synthesis and structure activity relationship (SAR) of a series of fused cyclopropyl- Received 3 January 2018 3-amino-2,4-oxazine (2-oxa-4-azabicyclo[4.1.0]hept-3-en-3-amine)-containing BACE inhibitors is Revised 24 January 2018 described. Through these efforts compound 2 was identiﬁed as a potent (cell IC = 15 nM) BACE inhibitor Accepted 26 January 2018 with acceptable ADME properties. When tested in vivo, compound 2 demonstrated a signiﬁcant reduc- Available online 1
Bioorganic & Medicinal Chemistry Letters – Elsevier
Published: Apr 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud